

From: AgingCare Exclusive Offers <exclusiveoffers@agingcare.com>
To: Kester, Tonykester@aging.sc.gov
Date: 12/1/2015 9:16:32 AM
Subject: Introducing a new option for moderate to severe Alzheimer's disease

From AgingCare.com: Below is an important message from our partner which may be of value to you and your family.

NAMZARIC is approved for the treatment of moderate to severe Alzheimer's disease in patients who are currently taking and can continue to take certain doses of both NAMENDA® (memantine HCl) or NAMENDA XR® (memantine HCl) extended release and donepezil HCl, the active ingredient in Aricept®. NAMZARIC is available by prescription only. NAMZARIC should not be taken by anyone who has an allergy to memantine HCl, donepezil HCl, medicines that contain piperidines, or any of the ingredients in NAMZARIC. See below for additional Important Safety Information.

Please see full Prescribing Information, including Patient Information.

Introducing NAMZARIC, the **FIRST AND ONLY** treatment for moderate to severe Alzheimer's disease that **combines 2 proven medicines**, NAMENDA XR and donepezil HCl, in a single, once-a-day capsule.

NAMZARIC is approved for the treatment of moderate to severe Alzheimer's disease in patients who are currently taking and can continue to take certain doses of both NAMENDA or NAMENDA XR and donepezil HCl, the active ingredient in Aricept. NAMZARIC is available by prescription only.

With NAMZARIC, you may see:

- An improvement in cognition, also known as mental function
- An improvement in overall function
- A slowdown in the worsening of symptoms for a while

There is no evidence that NAMZARIC prevents or slows the underlying disease process in patients with Alzheimer's disease.

[Learn more about NAMZARIC](#).

Learn about a 30-day Trial Offer at \$0 out-of-pocket cost.*

Learn how to start your loved one on NAMZARIC.

*Restrictions apply. See Trial Offer for details.

IMPORTANT RISK INFORMATION

Who should not take NAMZARIC?

NAMZARIC should not be taken by anyone who has an allergy to memantine HCl, donepezil HCl, medicines that contain piperidines, or any of the ingredients in NAMZARIC.

What should be discussed with the healthcare provider before taking NAMZARIC?

Before starting NAMZARIC, talk to the healthcare provider about all of the patient's medical conditions, including:

- heart problems including an irregular, slow, or fast heartbeat
- asthma or lung problems
- seizures
- stomach ulcers
- bladder, kidney, or liver problems
- any surgical, dental, or other medical procedures scheduled when anesthesia may be used

Tell the healthcare provider about all the medicines the patient is taking, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of NAMZARIC?

NAMZARIC may cause serious side effects, including:

- muscle problems in patients given anesthesia
- slow heartbeat and fainting. This happens more often in people with heart problems. Call the doctor right away if the patient faints while taking NAMZARIC
- more stomach acid. This raises the chance of ulcers and bleeding especially when taking NAMZARIC. The risk is higher for patients who have had ulcers, or take aspirin or other NSAIDs
- nausea and vomiting
- difficulty passing urine
- seizures
- worsening of lung problems in people with asthma or other lung disease

The most common side effects of memantine HCl include: headache, diarrhea, and dizziness.

The most common side effects of donepezil HCl include: diarrhea, not wanting to eat (anorexia), and bruising.

These are not all the possible side effects of NAMZARIC.

[Please see full Prescribing Information, including Patient Information.](#)

PLEASE NOTE: DO NOT REPLY TO THIS EMAIL. Emails sent to this account will not be read.

We respect your privacy. See our [Privacy Policy](#).

For additional information about NAMZARIC, call Actavis, Inc. toll-free at 1.844.626.9274.

Harborside Financial Center
Plaza V, Suite 1900
Jersey City, NJ 07311

NAMENDA®, NAMENDA XR®, NAMZARIC™ and their designs are trademarks of Merz Pharma GmbH & Co. KGaA.
Actavis® and its design are trademarks of Actavis, Inc., an Allergan affiliate.
Aricept® is a trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.
© 2015 Allergan. All rights reserved. NMZ38459 11/15

This message was intended for kester@aging.sc.gov. You received this e-mail because our records indicate that you're willing to receive offers from AgingCare.com and our partners. If you no longer wish to receive such offers, [unsubscribe here](#).

AgingCare.com | 9015 Strada Stell Court, Suite 203 | Naples, FL 34109